Session » Systemic Sclerosis and Related Disorders – Clinical Poster II
- 9:00AM-11:00AM
-
Abstract Number: 1730
A Role for Duplex Ultrasound of Hand Arteries in the Assessment of the Vasculopathy Associated to Systemic Sclerosis-like Diseases
- 9:00AM-11:00AM
-
Abstract Number: 1732
Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines
- 9:00AM-11:00AM
-
Abstract Number: 1734
Association of Short-Term Longitudinal Changes in Clinical and Physiologic Variables with Overall Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
- 9:00AM-11:00AM
-
Abstract Number: 1738
Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension
- 9:00AM-11:00AM
-
Abstract Number: 1735
Diagnostic Accuracy of MR Angiography in a Cohort with Systemic Sclerosis Compared to Other Rheumatic Diseases with Acral Hypoperfusion
- 9:00AM-11:00AM
-
Abstract Number: 1741
Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1742
Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1724
Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series
- 9:00AM-11:00AM
-
Abstract Number: 1740
Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
- 9:00AM-11:00AM
-
Abstract Number: 1716
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo
- 9:00AM-11:00AM
-
Abstract Number: 1717
Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study
- 9:00AM-11:00AM
-
Abstract Number: 1725
Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study
- 9:00AM-11:00AM
-
Abstract Number: 1719
High-Throughput Quantitative Histology in Systemic Sclerosis Skin Disease Using Computer Vision
- 9:00AM-11:00AM
-
Abstract Number: 1720
Higher Neutrophil Count Predicts More Severe Skin/Lung Disease and Increased Mortality in Early Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1736
Incidence and Risk Factors for Gangrene in Patients with Systemic Sclerosis from the Eustar Cohort
- 9:00AM-11:00AM
-
Abstract Number: 1729
Increased Risk of Valvular Heart Disease in Patients with Systemic Sclerosis: Results from a Population-Based Cohort (1980-2016)
- 9:00AM-11:00AM
-
Abstract Number: 1723
Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up
- 9:00AM-11:00AM
-
Abstract Number: 1737
Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide
- 9:00AM-11:00AM
-
Abstract Number: 1722
Patient-Level Factors Associated with Hospital Readmission Among Patients with Systemic Sclerosis Associated Pulmonary Hypertension
- 9:00AM-11:00AM
-
Abstract Number: 1728
Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation
- 9:00AM-11:00AM
-
Abstract Number: 1744
Prognostic Value of Right Heart Involvement in Systemic Sclerosis:Not Only Pulmonary Arterial Hypertension
- 9:00AM-11:00AM
-
Abstract Number: 1727
Prospective Confirmation of Potential Link between Proton Pump Inhibitor Exposure and Calcinosis in Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1721
Racial Differences in SSc Disease Presentation: A Cross-Sectional European Scleroderma Trials and Research Group Study
- 9:00AM-11:00AM
-
Abstract Number: 1715
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
- 9:00AM-11:00AM
-
Abstract Number: 1743
Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach
- 9:00AM-11:00AM
-
Abstract Number: 1726
Sexual Dysfunction in Systemic Sclerosis Female Patients
- 9:00AM-11:00AM
-
Abstract Number: 1733
Should We Perform Exercise Echocardiogram As a Screening Test for Pulmonary Arterial Hypertension (PAH) for All Systemic Sclerosis (SSc) Patients?
- 9:00AM-11:00AM
-
Abstract Number: 1718
Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change
- 9:00AM-11:00AM
-
Abstract Number: 1731
Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma